pargyline has been researched along with Basal Ganglia Diseases in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parenti, M | 1 |
| Flauto, C | 1 |
| Parati, E | 1 |
| Vescovi, A | 1 |
| Groppetti, A | 1 |
| Heintz, R | 1 |
| Casey, DE | 1 |
2 other studies available for pargyline and Basal Ganglia Diseases
| Article | Year |
|---|---|
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Drug Syn | 1986 |
Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys.
Topics: Animals; Basal Ganglia Diseases; Cebus; Corpus Striatum; Dopamine; Dystonia; Female; Haloperidol; Ma | 1987 |